Podcasts about Roberts

Play Episode Listen Later Dec 21, 2025 2:08

Nicola Longo MD, PhD, and Mark Roberts, MDNicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs.Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025 and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas.In this part, Dr. Roberts will discuss lessons learned from gene therapy trials.Mark Roberts, MDWhen we think about the challenges of actually doing clinical trials with these gene therapies, there's a huge development stage in terms of picking the right viral vector with the right surface receptor. That's a major piece of work. That can often take years. The preclinical work is obviously very important as indeed is understanding the natural history because it's really not practical to do placebo-controlled trials of gene therapies.In contrast to other studies, when we turn to phase 1 and phase 2, you'll notice that the patient numbers are often quite small. One is having to think carefully about surrogate measurements of response. Especially when in phase 3 studies, we may be thinking about withdrawing the existing, for example, enzyme replacement therapy because we believe the gene therapy will then be effective.That's just a few snapshots of where we've come and there's a lot more work to be done.In the next part, Dr. Longo will discuss the current treatment landscape and limitations in lysosomal disorders.

university california los angeles phd san diego trials manchester roberts vice chair longo gene therapy lessons learnt human genetics los angeles ucla mark roberts astellas consultant neurologist clinical genetics world symposium mdprofessor phdprofessor

Chapter 5: Current Treatment Landscape and Limitations

Play Episode Listen Later Dec 21, 2025 9:01

Nicola Longo MD, PhD, and Mark Roberts, MDDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at WORLDSymposium 2025 in San Diego, California on February 4th-7th 2025 and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses.The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Longo will discuss the current treatment landscape and limitations in lysosomal disorders.Nicola Longo MD, PhDWhat I want to do today, is just place gene replacement therapy within the current landscape of lysosomal storage disorder treatment therapy. Gene therapy obviously has the potential of treating lysosomal disorder to correct the root cause of lysosomal storage disorder. The gene is defective, and what happen is that you can potentially either fix the gene or bypass the lack of the genetic product. But there are already therapies that are existing and are functioning. Obviously, in many cases, the lysosomal disorder is caused by defective production of an enzyme, which is defective.We can either replace the enzyme with enzyme replacement therapy, or provide chaperone for specific mutations that retain the synthesis of the enzyme, that however is not very functional. Another avenue that it is being reported is the utilization of substrate reduction therapy. A substrate accumulates, you prevent the synthesis of the substrate to reduce the accumulation of toxic material. What we know now is that this is not enough to produce many lysosomal disorders. In many cases, the lysosomal disorder result sometime in impairment of intracellular trafficking, and sometime in the function of other organelles.At the end, it results in the activation of the macrophagic system and inflammation. Already we have some therapy acting at this level. The end result of lysosomal storage disorder, there will be cell suffering and cell death, leading to a progression of the disease, and morbidity and mortality. Now, what therapy do we have available already? Obviously, hematopoietic stem cell transplantation has been around for quite some time.It has been the same thing that we do with gene therapy, except that instead of reintroducing the gene of the subject, we place gene of a subject who is not affected of the disease. This therapy has been proven effective in cases of MPS-1 and alpha-mannosidosis. But in many cases this has to be given way before symptoms start to be affected.Enzyme replacement therapy has been around for quite some time, starting with Gaucher disease, and now that it is available for a list of diseases that are there, so it's like Fabry, Gaucher, Pompe, different types of mucopolysaccharidosis, alpha-mannosidosis, acid lipase deficiency, 1 neuronal ceroid lipofuscinosis, and Niemann-Pick type A and B.Obviously the advantage of this therapy, they give back the enzyme that it is defective. But the disadvantage that many time they cannot enter specialized areas such as the brain. There is already the second generation of enzyme replacement therapy that it is available. With this second generation, some of the newer drugs are more effective in terms of cellular uptake, or in terms of having a prolonged half-life and prolonged activity.Then there are pharmacological chaperone therapy, and the one which is FDA approved is migalastat for Fabry disease, under study is ambroxol for Gaucher disease. The disadvantage of this therapy that only a selected number of mutations respond to this therapy.Substrate reduction therapy has been introduced for Gaucher disease many years ago with miglustat, and it was followed by eliglustat. Both of them are effective, and some of them more effective than other, simply because of the fewer side effects of eliglustat as compared to miglustat. But at the same time, eliglustat does not pass the blood brain barrier.Finally, the newer agents that are already administered, N-acetyl-L-leucine and arimoclomol, both approved for Niemann-Pick type C, they act more on the downstream effect of the lysosomal storage disorder, either by stabilizing neuronal cell activity or by reducing the inflammation that is present in the brain.In the next part, Dr. Longo will discuss gene replacement therapy in lysosomal disorders.

california phd current san diego treatments landscape fda roberts limitations mps longo enzyme pompe substrate mark roberts fabry gaucher astellas niemann pick

Chapter 8: Gene Therapy Discussion and Q&A

california phd san diego roberts rna longo gene therapy crispr cas9 aav ert mdi mark roberts astellas world symposium

Play Episode Listen Later Dec 21, 2025 10:28

Nicola Longo MD, PhD, and Mark Roberts, MDDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025, and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas.In this part, Doctors Roberts and Longo will discuss treatment with gene therapies.Question: Can one administer AAV-mediated gene therapy repeatedly?Mark Roberts, MDI think the traditional view would have been no. One can think of gene therapy as a silver bullet. Hopefully, it will reach its target. But if it's not effective, that bullet has been shot, the immunological response has occurred, and it means redosing, at least with that particular vector, may become difficult. But this situation is changing and evolving as we have better understanding of immunological modulation for repeat testing. We were discussing this yesterday evening, weren't we, Professor Longo?Nicola Longo MD, PhDCorrect. Basically, the current AAV-based gene therapy cannot be readministered. It is either effective, or it doesn't work. The other thing is that even though in theory, one could utilize a different AAV vector with different immunogenicity, there is many times cross-reactivity among the different adenovirus, adeno-associated viruses. Now, there are approaches in animal models in which you give a strong immune suppression to prevent the creation of the immune response against the adeno-associated virus, and at least in the animal model, it has been possible to give some of the gene therapy repeatedly.The second approach that is being tested is with gene correction therapy, in which by using an RNA guide and the CRISPR/Cas9 system delivered by lipid nanoparticles, you basically correct some of the effective genetic information. Obviously, since this is done by lipid nanoparticles and not by an AAV, the immunity that you create is really not there. You can give this one repeatedly, and in theory, it can be given more than one time. But again, you are absolutely correct. The current gene therapy cannot be given twice, and either it works or it doesn't work.Question:vWill gene-therapy-treated patients be able to go back to the standard of care or enzyme replacement therapy?Mark Roberts, MDI think when we're talking to patients about the potential benefits of gene therapy and the amelioration of the requirement to have these infusions on a regular basis of ERT, the hope is that will work, but they need to be reassured that we can potentially go back to the ERT. Gene therapy is an important treatment, but we don't know the destination of the patient at the beginning, and we have to make it available to them to go back to ERT.One of the crucial questions, of course, though, is the basis of the immunological reaction that perhaps prevented the gene therapy being effective. If it's against the viral vector, well, okay. If it's against the transgene, not great. If it's against the functional protein, that becomes more difficult. It is somewhat, I think at this time, to be fair to say to patients, think of gene therapy as a trial treatment. It is somewhat a leap of faith and an important observation, of course, for the patient community, but just be aware there may be downsides.Nicola Longo MD, PhDThey totally agree with Dr. Roberts. In general, they should be able to go back to enzyme replacement therapy if the gene therapy is not effective. However, what we are starting to appreciate is that we need to understand the immune response, not just to the enzyme replacement therapy, but also to gene therapy. What this field is doing is forcing geneticists to deal with the immune response. I feel that historically has not been dealt together. The two things need to be integrated. The advantage of the gene therapy is that the protein is produced endogenously. There should be the development of some degree of tolerance with time in the body towards the endogenous continuous production of a protein.Now, will that happen all the time? I still do not know. Again, we need to understand much better what is the integration of the immune system with the response to gene therapy in the ongoing clinical trials.

Chapter 6: Gene Replacement Therapy in Lysosomal Disorders

Play Episode Listen Later Dec 21, 2025 3:38

Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight part podcast series. This is derived from the symposium that was presented at World Symposium 2025, in San Diego, California, on February 4th through 7th, 2025, and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established, and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Longo will discuss gene replacement therapy in lysosomal disorders.Nicola Longo MD, PhDLet's go back a second to gene therapy. Gene therapy obviously has the potential of answering many of the questions that we still have open in lysosomal disorder because they could restore the activity of the lysosome pretty much in the whole body, or at least in multiple tissues. As you have seen, gene therapy can be done ex vivo where we take cells from the affected patient, we correct the gene, or we put an extra gene that it is functional. Then we put them back by doing a bone marrow transplant, basically creating space for the cells that have been genetically modified to correct the lysosomal defect. The biggest approach this is done usually by lentiviruses that they integrate inside the genome.

university california los angeles therapy san diego manchester roberts disorders replacement vice chair longo human genetics los angeles ucla astellas consultant neurologist clinical genetics world symposium mdprofessor phdprofessor

Chapter 3: Immune Responses and Other Safety Concerns Related to Gene Therapies

Play Episode Listen Later Dec 21, 2025 4:50

Nicola Longo MD, PhD, and Mark Roberts, MDNicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfesor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this 8-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th-7th 2025 and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses.The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Roberts will discuss immune responses and other safety concerns related to gene therapies.Mark Roberts, MDUndoubtedly, the immune system is a major issue in these patients. It would be fantastic if we could immunotolerize our patients and indeed prevent the rejection of the therapy. We've talked about the fact that these are viral vectors and of course there may be high seroprevalence of antibodies to these viral vectors, and it's very important in the pre-screening of patients who might be eligible to understand that at the beginning. These of course can have developed over the years and of course can be part of immunological memory and therefore extremely difficult and probably impractical to actually shift.On giving the treatment though as I think we're all aware there is this problem of the innate immunity and potential therefore for acute toxicities and then a learned or adaptive response with cytotoxic T cells and antibodies which may of course become high tighter neutralizing antibodies and potentially antibodies not only against the viral vector, even the functional protein, even the transgene are all theoretical possibilities with time. The capsid, the transgene, and even the protein product can all potentially induce an immunological event. Of course, all of these would lead to both potential patient changes and then a lack of efficacy of the treatment.Indeed, there have been some serious and indeed fatal problems in the gene therapy development program as I think we're all aware. Though many of these are thankfully been overcome. Spinal muscular atrophy has a gene therapy which is licensed, but there were early patients who actually had significant problems. A patient of just 6 months of age who developed kidney failure, two other patients who actually developed liver failure.In Duchenne muscular dystrophy, a very common condition, again there were significant issues and crucially in these patients who all have cardiomyopathy, it was heart failure and cardiac arrest that were big concerns and pulmonary edema and this was seen even with a CRISPR-based technology and is perhaps is best known but has been addressed the excellent myotubular myopathy patients, four patients died and crucially quite a long time after the gene therapy emphasizing the need to monitor these patients extremely carefully and these patients died of cholestatic liver failure albeit that they had a degree of liver dysfunction.That's changed our screening of course of patients, we're now all looking in myotubular patients for liver involvement and Rett syndrome as well. Now these immunoprophylaxis treatment regimes to hopefully try and reduce the immunological reaction against the gene are certainly evolving.This is just a summary of some of the other immunosuppressive regimes used in other disorders, for example, spinal muscular atrophy, but Pompe and MPS as examples of LSDs. Certainly these regimes will continue to evolve and are going to be very important in seeking to make sure that these treatments are effective. It reminds me somewhat of what's happened with enzyme replacement therapy that the use of these immunological strategies in infants has revolutionized the utility of those treatments in early patients.In the next part, Dr. Roberts will discuss lessons learned from gene therapy trials.

Chapter 2: Vectors, Different Strategies, Modes of Administration, and Targets

Play Episode Listen Later Dec 21, 2025 8:59

Nicola Longo MD, PhD, and Mark Roberts, MD Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfesor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025 and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice.The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Roberts will discuss vectors, different strategies, modes of administration and targets in gene replacement therapies.Mark Roberts, MDNow in the broader sense, gene replacement therapy seeks to actually deliver genetic material directly into the host cell to influence gene expression. In the most simple idea, one of course has a vector, this is most commonly but not exclusively a virus, which can then be given intravenously for example, and can hope to potentially correct the condition within the individual cells using novel transgenes. Suitable candidate conditions for this as examples of genetic conditions are now well understood. And crucially, this applies not only towards some more recessive, but dominant and even accident conditions.Across the piece, one can see for example, mitochondrial problems, spinal muscular atrophy as is well known, X-linked myotubular myopathy, Duchenne muscular dystrophy, a very common condition affecting one in 3000 male individuals, Pompe disease of course, an important focus of the meeting here, but other very common conditions, for example, cystic fibrosis, immunological conditions and perhaps obviously very crucial in early work on gene therapy, hemophilia.Let's now think about the approaches to gene therapy. One can seek to work at the DNA level and gene replacement. In essence, one is trying to put a new transgene through into the nucleus that will ultimately be transcribed and translated and produce the important functional protein that is lost. Gene editing which is a very exciting new technology or CRISPR technology actually seeks to actually modify in vivo the actual mutations that are responsible for the pathogenic production of abnormal proteins and correcting these and actually producing a more normalized protein.But of course there are also RNA approaches where one seeks to actually repair the mRNA transcripts copied from the mutated gene. For example, this may be a novel approach that could be extremely useful in myotonic dystrophy, a multisystem condition. When we talk about the viral vectors, predominantly we're talking about viruses. Those such as adenoviruses and AAV viruses which have the virtue of not integrating into the host genome or at least not in a large amount, and those which deliberately seek to integrate into host genome such as retroviral or lentiviral systems that may be particularly useful for ex vivo systems.There are of course other ways to get genetic payloads into the nucleus, various polymers, nanoparticles and even cell penetrating peptides. Nanoparticles in particular is certainly on the ascendant. That being said, in a recent review of the clinical trials in gene therapy, it was certainly the viral vectors that stood out both in direct gene replacement with lentivirus and AAV, but also actually as delivery systems, for example, for gene editing. An example of what one is seeking to do with AAV, so of course one seeking to remove the native DNA, insert the new transgene directly into the vector and of course keen to make sure that there's a high transmission into the capsid producing a recombinant AAV, which then can be given as a treatment and hopefully produce a therapeutic increase in the functional protein that is deficit in the disorder.In the next part, Dr. Roberts will discuss immune responses and other safety concerns related to gene therapies.

Chapter 7: Ongoing Gene Therapies in Lysosomal Disorders

Chelsea Against The World

Play Episode Listen Later Dec 21, 2025 8:39

Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025, and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Longo will discuss ongoing gene therapies in lysosomal disorders.Nicola Longo MD, PhDI'm going to present to discuss some example of ongoing gene therapy for lysosomal disorder. There are gene therapy in development for both Fabry disease and some of this involve ex vivo gene therapy, many others involve systemic administration with an AAV, Gaucher disease type 1 that affect the periphery, and Gaucher disease type 2, where the replacement should occur within the central nervous system because this condition affects the brain. There is already one approved gene therapy for lysosomal disorder, which is for the early onset metachromatic leukodystrophy. This has been approved both in Europe and now even in the United States, which consists of ex vivo gene therapy with the administration of an extra gene that restore the function of the defective enzyme. Now there are many others that are ongoing for the same indication. There are gene therapy programs for GM1 and GM2 gangliosidosis, and at least one for Krabbe disease. It is important to know that some of these condition are actually included in the recommended uniform screening panel. Basically, we would have access to patients in a timely manner for some of these conditions. Then there are several gene therapy under development for the mucopolysaccharidoses, including MPS-IH, MPS-II, MPS-IIIA and MPS-IV.There are different type of lysosomal disorders, the one caused by mutation, integral membrane protein, not enzyme within the lysosome, but protein that are present on the membrane of the lysosome. This gene therapy that have been tested, it is for cystinosis, that it is caused by a defective lysosomal and for Danon disease, which is caused by a deficiency of an integral membrane part. Finally, one lysosomal disorder, which obviously seems a metabolic condition, but it is really not, is glycogen storage disease type 2 or Pompe disease, in which there is the intralysosomal accumulation of glycogen. There are several ongoing clinical trials to try to correct the problem in this condition.Now, I'm going to discuss some of the most advanced program in the lysosomal storage disorder. This include one for Fabry, which is on an accelerated approval pathway with phase 1 and 2 data, one for Gaucher disease type 1. Obviously, I'm going to discuss the one that has been already approved for metachromatic leukodystrophy. There is one for Hunter syndrome, and the difference of the one for Hunter syndrome, it is an example of the direct administration of gene therapy within the central nervous system.Finally, there is one ongoing for glycogen storage disease type 2 or Pompe disease in adult patients. In gene therapy for metachromatic leukodystrophy, it was the first gene therapy approved for lysosomal disorder in human, and this requires harvesting the CD34 cell from affected patient and then introducing the [inaudible 00:04:32] gene back in this cell, and then placing them back inside the patient again. This has been very effective in patients who were treated early, and obviously, the treatment needs to occur before there is irreversible brain damage in this patient.In the next part, Dr. Roberts and Longo will discuss treatment with gene therapies.

Episode 147 – Chelsea Rescue a Point at Newcastle | From Disaster to Determination

Play Episode Listen Later Dec 20, 2025 47:00

Chelsea show real fight as the Blues come from 2-0 down to draw 2-2 away at Newcastle on Saturday. Manny and Simon review a truly shocking first half, before an incredible second-half turnaround that showed resilience, leadership, and belief.The hosts highlight standout performances from Reece James, João Pedro, and Robert Sánchez, all of whom played huge roles in dragging Chelsea back into the game. They also dig into the big question — why did Chelsea start so poorly, and how were they able to recover so dramatically after the break?Finally, attention turns to another massive test, with a preview of next weekend's clash against high-flying Aston Villa, as Chelsea look to build on this hard-earned point.

blues disasters rescue grit roberts newcastle determination manny aston villa

TRUCKSTOP: The Disappearances of Caleb Smith & Keeslyn Roberts

Missing Persons Mysteries

Play Episode Listen Later Dec 20, 2025 18:34 Transcription Available

TRUCKSTOP: The Disappearances of Caleb Smith & Keeslyn RobertsBecome a supporter of this podcast: https://www.spreaker.com/podcast/missing-persons-mysteries--5624803/support.

lost missing mysteries roberts lore disappearances stockton unsolved vanished disappeared truckstop caleb smith

LA GUERRA DE CHARLIE WILSON | UNA HISTORIA TAN ABUSRDA QUE TIENE QUE SER CIERTA

Cinefilia y Otras Hierbas

Play Episode Listen Later Dec 20, 2025 116:31

Bienvenidos, cinéfilos hierberos, a un nuevo episodio de Cinefilia y Otras Hierbas, cine, televisión, música y videojuegos para escuchar.Hoy, continuamos con nuestro ciclo dedicado al gran Aaron Sorkin –ese maestro del diálogo afilado que nos hace creer que la política puede ser tan entretenida como un partido de tenis verbal–, nos sumergimos en Charlie Wilson's War, esa película del 2007 que, admitámoslo, no es la primera que viene a la mente cuando pensamos en su filmografía, pero que destila ese ingenio sorkiniano que tanto adoramos.Imaginemos el panorama: finales de los años 80, la Guerra Fría en su apogeo, y un congresista texano llamado Charlie Wilson –conocido como "Good Time Charlie" por su afición a las fiestas, el whiskey y las compañías femeninas– que, de repente, se convierte en el artífice de la operación encubierta más grande de la historia de la CIA. La película se basa en el libro homónimo de George Crile, un tomo de 500 páginas repleto de detalles históricos que Sorkin adaptó con maestría, condensando intrigas geopolíticas en diálogos que chisporrotean como fuegos artificiales. ¿Cómo llegó Sorkin al proyecto? Pues, en un raro acto de agresividad profesional –él mismo lo admite–, leyó el libro y lo persiguió con ahínco, convirtiéndolo en el único guion que ha "cazado" de esa manera. Y vaya si lo logró: su énfasis en los personajes imperfectos pero heroicos, como Wilson, que pasa de playboy a salvador de los muyahidines afganos, es puro Sorkin, recordándonos sus obras como The West Wing, donde la burocracia se vuelve poesía.Tom Hanks interpreta a Wilson con esa calidez hankiana que hace que hasta un político corrupto parezca simpático. Detrás de cámaras, el director Mike Nichols, en lo que sería su última película, aportó su toque magistral y supo manejar el caos de enemigos históricos colaborando –pakistaníes, israelíes, afganos– en la narrativa real, algo que el guion de Sorkin plasma con ironía sutil.Julia Roberts, Philip Seymour Hoffman, Amy Adams, Ned Beatty y Emily Blunt completan la constelación de estrellas de este filme que cuenta una historia tan absurda, que no puede sino ser cierta....¡Y lo es!La película fue bien recibida en general, con un 82% de aprobación en Rotten Tomatoes, donde se alaba cómo "entretiene e informa" gracias al guion astuto de Sorkin y actuaciones sólidas. Muchos críticos la vieron como una excelente comedia oscura basada en hechos reales, destacando a Hanks como un antihéroe encantador. Sin embargo, no todo fue aplausos: algunos la tildaron de "falsa y nada divertida", con "la peor actuación de la carrera de Roberts" En premios, brilló con 5 nominaciones a los Globos de Oro –mejor película comedia, actor para Hanks, actriz de reparto para Roberts, actor de reparto para Hoffman y guion para Sorkin–, más una nominación al Oscar para Hoffman como mejor actor de reparto. La Guerra de Charlie Wilson es, quizá, la película menos conocida y popular de Sorkin –eclipsada por hits como La Red Social o El Juicio de los 7 de Chicago–, y tal vez la más "floja" de su catálogo. Pero, no les quepa duda, incluso una "floja" de Sorkin es mejor que muchas de las producciones que inundan las pantallas hoy en día: cargada de inteligencia, humor sofisticado y una lección histórica que, con un guiño irónico, nos recuerda que la política puede ser absurdamente entretenida. ¿Listos para desentrañar más? ¡No se pierdan el episodio!Patreon: patreon.com/cinefiliayotrashierbas⁠Correo: cinefiliayotrashierbas@gmail.com No olviden suscribirse, compartir este episodio y dejar un comentario y un like, eso nos ayudará a crecer y a encontrar más audiencia. ¡Que lo disfruten!#AaronSorkin⁠ ⁠#TomHanks⁠ ⁠#Cine⁠ ⁠#JuliaRoberts

Christmas, Christianity, Controversy & Commercialization | S5Bonus Christmas

History Behind News

Play Episode Listen Later Dec 19, 2025 63:06

Why Dec. 25? Why so much Christmas conflict & controversy in Christianity's history? Why is Christmas so important to Christianity? And to America? In this episode, I ask my guest, Dr. Carey Roberts, the following questions: ►Why is Christmas such a grand celebration? What does this tell us about Christianity? ►Did it take a while for Christmas to take a central role in Christianity►What's the difference between recognition and celebration of Christmas►Did Christmas piggyback on existing Roman pagan traditions? ►How did Christmas enter America's culture? If not the Puritans, then which immigrant group introduced Christmas to America? ►Were there any regional differences in the celebration of Christmas?►When did U.S. businesses begin to capitalize on Christmas? ►Would President Grant have witnessed a similar Christmas celebration in Boston and Savannah? ►Would George Washington recognize our Christmas? How about Andrew Jackson? Abraham Lincoln? Teddy Roosevelt? ►What happened to Christmas after WWII? ►Is it a bad thing that non-Christians and/or non-practicing Christians celebrate Christmas? ⁠

FULL SHOW: Thursday, December 18th

The Valenti Show

Play Episode Listen Later Dec 18, 2025 139:46

Valenti and Rico started the show with their thoughts on what WFAN's Evan Roberts had to say about his confidence in the Knicks in a potential playoff series with the Pistons. They spent some time discussing why they all disagree with Roberts before they shifted to break down some recent comments from Kelvin Sheppard about his satisfaction with how his defense has played recently. The guys had an unconventional third hour, which included a Christmas movie draft and then ended the show with their disappointment with Michigan football's strict policy when it comes to asking its players about Sherrone Moore.

christmas sports michigan rico roberts new york knicks detroit pistons wfan sherrone moore valenti evan roberts

Guest: Phranq Tamburri -- Topic: Trump Report -- Hour 1

Declare Your Independence with Ernest Hancock - Radio

Play Episode Listen Later Dec 18, 2025 186:00

donald trump freedom player active stream roberts

Bluegrass Unlimited Podcast with Jaelee Roberts

Bluegrass Unlimited's Podcast

Play Episode Listen Later Dec 18, 2025 61:38

This week we feature Jaelee Roberts, the lead singer and guitar player for Sister Sadie. We talk with Jaelee about growing up in a prominent bluegrass family, performing with an award-winning band, recording her solo albums and performing on the Grand Ole Opry. You will also hear a couple of songs from Jaelee's newest solo album.

roberts bluegrass grand ole opry sister sadie

Re-Storying Education with Carolyn Roberts

Teach Outdoors

Play Episode Listen Later Dec 18, 2025 34:50

In this episode of the Teach Outdoors Podcast, Lauren MacLean is joined by educator, writer, and author Carolyn Roberts, whose work centers on re-storying education through story, land-based learning, and relational ways of knowing.Carolyn invites us to slow down and reconsider the stories that shape our classrooms, our relationships, and our responsibilities to land and community. Together, Lauren and Carolyn explore how story is not just something we teach, but something we live — and how children's literature, particularly picture books by Indigenous authors, can open meaningful conversations about identity, belonging, and land.This conversation gently supports educators who may feel unsure or fearful about “getting it wrong,” offering practical, grounded ways to begin engaging in decolonizing practices with humility, reflection, and care. From using picture books as entry points, to rethinking land acknowledgements, to honouring children as knowledge holders, this episode offers reassurance that this work doesn't require perfection — only presence.This is a reflective and hopeful conversation for educators at any stage of their journey.Carolyn's WebsiteCarolyn's Journal Article

education indigenous roberts journal article storying

12/11/25 Bob Murphy on How Central Banking Fuels the War State

The Ryan Kelley Morning After

Play Episode Listen Later Dec 17, 2025 85:39

Scott interviews economist Bob Murphy about how the Federal Reserve enables the government to pursue its wars of choice. They also talk about the soundness of Modern Monetary Theory, the prospect of a war with Venezuela, the affordability crisis and more. Discussed on the show: The Creature from Jekyll Island by G. Edward Griffin What Has Government Done to Our Money? by Murray Rothbard Secrets of the Temple: How the Federal Reserve Runs the Country by William Greider Politically Incorrect Guide to the Great Depression and the New Deal by Robert P. Murphy Robert P. Murphy is a Senior Fellow with the Mises Institute. He is the author of numerous books: Contra Krugman: Smashing the Errors of America's Most Famous Keynesian; Chaos Theory; Lessons for the Young Economist; Choice: Cooperation, Enterprise, and Human Action; The Politically Incorrect Guide to Capitalism; Understanding Bitcoin (with Silas Barta), among others. He is also host of The Human Action Podcast and The Bob Murphy Show. Follow him on X @BobMurphyEcon Audio cleaned up with the Podsworth app: https://podsworth.com Use code HORTON50 for 50% off your first order at Podsworth.com to clean up your voice recordings, sound like a pro, and also support the Scott Horton Show! For more on Scott's work: Check out The Libertarian Institute: https://www.libertarianinstitute.org Check out Scott's other show, Provoked, with Darryl Cooper https://youtube.com/@Provoked_Show Read Scott's books: Provoked: How Washington Started the New Cold War with Russia and the Catastrophe in Ukraine https://amzn.to/47jMtg7 (The audiobook of Provoked is being published in sections at https://scotthortonshow.com) Enough Already: Time to End the War on Terrorism: https://amzn.to/3tgMCdw Fool's Errand: Time to End the War in Afghanistan https://amzn.to/3HRufs0 Follow Scott on X @scotthortonshow And check out Scott's full interview archives: https://scotthorton.org/all-interviews This episode of the Scott Horton Show is sponsored by: Roberts and Roberts Brokerage Incorporated https://rrbi.co Moon Does Artisan Coffee https://scotthorton.org/coffee; Tom Woods' Liberty Classroom https://www.libertyclassroom.com/dap/a/?a=1616 and Dissident Media https://dissidentmedia.com You can also support Scott's work by making a one-time or recurring donation at https://scotthorton.org/donate/https://scotthortonshow.com or https://patreon.com/scotthortonshow Learn more about your ad choices. Visit megaphone.fm/adchoices

TMA (12-17-25) Hour 3 - When The Tiger Nationalists Get Ya

Play Episode Listen Later Dec 17, 2025 33:19

(00:00-21:58) Doug knows The Weeknd. Jackson explains Tiger Nationalists. Burner accounts are the most courageous. Jackson wants to give proper context so we're gonna hear some audio. First up is Drink talking about trying to find a way to keep Jamal Roberts in Columbia. Next up is Ahmad Hardy talking about other teams not contacting him because they know he's a Tiger. And now audio from BK & Ferrario commenting on the Jamal Roberts/NIL situation saying Roberts should go look to get more carries elsewhere. Then the Tiger Nationalists came after them.(22:06-31:04) Light My Love. Josh Schertz will join us tomorrow. The Dish. SLU to the Big East would be a great thing. We will reconcile by winning.(31:14-33:10) Papers loves some CCR. Jackson's an old soul. The dichotomy of Papers. QFTA today.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

drink columbia tiger roberts weeknd papers dish bk big east burner nationalists ccr slu

12/11/25 Bob Murphy on How Central Banking Fuels the War State

The Libertarian Institute - All Podcasts

Play Episode Listen Later Dec 17, 2025 85:24

Download Audio. Scott interviews economist Bob Murphy about how the Federal Reserve enables the government to pursue its wars of choice. They also talk about the soundness of Modern Monetary Theory, the prospect of a war with Venezuela, the affordability crisis and more. Discussed on the show: The Creature from Jekyll Island by G. Edward Griffin What Has Government Done to Our Money? by Murray Rothbard Secrets of the Temple: How the Federal Reserve Runs the Country by William Greider Politically Incorrect Guide to the Great Depression and the New Deal by Robert P. Murphy Robert P. Murphy is a Senior Fellow with the Mises Institute. He is the author of numerous books: Contra Krugman: Smashing the Errors of America's Most Famous Keynesian; Chaos Theory; Lessons for the Young Economist; Choice: Cooperation, Enterprise, and Human Action; The Politically Incorrect Guide to Capitalism; Understanding Bitcoin (with Silas Barta), among others. He is also host of The Human Action Podcast and The Bob Murphy Show. Follow him on X @BobMurphyEcon Audio cleaned up with the Podsworth app: https://podsworth.com Use code HORTON50 for 50% off your first order at Podsworth.com to clean up your voice recordings, sound like a pro, and also support the Scott Horton Show! For more on Scott's work: Check out The Libertarian Institute: https://www.libertarianinstitute.org Check out Scott's other show, Provoked, with Darryl Cooper https://youtube.com/@Provoked_Show Read Scott's books: Provoked: How Washington Started the New Cold War with Russia and the Catastrophe in Ukraine https://amzn.to/47jMtg7 (The audiobook of Provoked is being published in sections at https://scotthortonshow.com) Enough Already: Time to End the War on Terrorism: https://amzn.to/3tgMCdw Fool's Errand: Time to End the War in Afghanistan https://amzn.to/3HRufs0 Follow Scott on X @scotthortonshow And check out Scott's full interview archives: https://scotthorton.org/all-interviews This episode of the Scott Horton Show is sponsored by: Roberts and Roberts Brokerage Incorporated https://rrbi.co Moon Does Artisan Coffee https://scotthorton.org/coffee; Tom Woods' Liberty Classroom https://www.libertyclassroom.com/dap/a/?a=1616 and Dissident Media https://dissidentmedia.com You can also support Scott's work by making a one-time or recurring donation at https://scotthorton.org/donate/https://scotthortonshow.com or https://patreon.com/scotthortonshow

Guest: James Corbett -- Topic: The Corbett Report -- Hour 1

Declare Your Independence with Ernest Hancock - Radio

Play Episode Listen Later Dec 17, 2025 54:43

freedom player active stream roberts james corbett corbett report

Elijah Roberts: Execution is Key | Salty Dogs

Salty Dogs

Play Episode Listen Later Dec 17, 2025 94:14 Transcription Available

Friend of the pod Elijah Roberts returns for another illuminating chat, while Jeff and Scott look back at the Falcons game and ahead to exciting three weeks coming up.See omnystudio.com/listener for privacy information.

dogs friend roberts atlanta falcons execution salty

Chapter 1: Lysosomal Disorders and the Potential for Gene Therapies

donald trump battle news records true crime roberts breaking news epstein jeffrey epstein expose courtroom ghislaine maxwell prince andrew jane doe objection viriginia

Play Episode Listen Later Dec 17, 2025 3:34

Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025, and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established, and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses.The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas.In this part, Dr. Roberts will discuss lysosomal disorders and the potential for gene therapies.Mark Roberts, MDI'm going to give an overview of what is gene therapy, emphasizing the current challenges and the development issues and needs that there will be as we try and enable gene therapy for our patients, particularly those with lysosomal storage disorders.I'm going to try and make a case for why lysosomal storage disorders are an extremely good group of conditions for the potential benefits of gene modifying therapies. Firstly, whilst we all recognize that these conditions are inherently individually rare, they're certainly severe. Collectively, with over 70 LSD disorders, 1 in 5,000 may be afflicted by these conditions ultimately in their life and can be detected, for example, by newborn screening programs.Secondly, there's certainly a significant clinical burden with these patients with the current standard of care, so a large unmet need exists. Existing enzyme replacement therapies have undoubtedly changed the natural history of many of these conditions, but there are limitations and often initial benefits and later deteriorations.Unfortunately, for most lysosomal storage disorders, it's only symptomatic treatments and indeed, care that is available for these patients with no specific treatment. Thirdly, these conditions are extremely well-characterized, monogenic singleton and problems of inborn errors of metabolism. We know the functional protein that is deficient in these conditions. Because of that, and knowing that these are critical for lysosomal function, and using preclinical models, we can model the potential benefits of gene therapies very well in a number of systems, including, of course, soon, muscle chip experiments as well.Finally, with these conditions, they may potentially be really useful targets whilst not perhaps curing the condition, at least ameliorating the phenotype, and enabling the addition of other treatments as well, potentially. I've noted, some of these therapies can be directly delivered to certain tissues, so muscle tissue, which is my main interest, but also, crucially, the central nervous system, which is very important when we consider ameliorated phenotypes, for example, treated by enzyme replacement therapy, but where the children who become the adults have significant learning disability as a major component to their problems.In the next part, Dr. Roberts will discuss vectors, different strategies, modes of administration, and targets in gene replacement therapies.

Viriginia Roberts And Her Battle In The Courtroom To Expose Jane Doe # 133

Beyond The Horizon

Play Episode Listen Later Dec 16, 2025 9:56 Transcription Available

Virginia Roberts is battling it out in court with someone known as Jane doe # 133. The battle has to do with Jane Doe's persistent resistance to her name being unsealed as part of the document dump initiated by Judge Preska. Virginia Roberts and her legal team say that transparency and the publics right to know outweighs Jane doe's right to privacy, considering she has already been named in public. Now it will be up to the court to decide.to contact me:bobbycapucci@protonmail.comsource:Jeffrey Epstein Victim Virginia Giuffre Fighting Jane Doe's Objection to Unsealing of Records (radaronline.com)

Guest: Alessandro Fusillo -- Topic: The Philosophy of Liberty -- Hour 1

Declare Your Independence with Ernest Hancock - Radio

Play Episode Listen Later Dec 16, 2025 74:35

freedom philosophy player active stream roberts

276. Leading from the Inside Out - Suzanne Roberts

IDEAS+LEADERS

Play Episode Listen Later Dec 15, 2025 26:56

In this episode of the IDEAS+LEADERS Podcast, I'm joined by Suzanne Roberts, transformational speaker, facilitator, and founder of UnifyingSolutions. Suzanne has spent more than four decades helping leaders and organizations create sustainable, systemic change, and is the creator of Polarity System Design™ – a methodology that helps people reclaim their inner capacity, lead with clarity, and design cultures rooted in purpose and equity.We explore what it really means to lead from the inside out – how unresolved patterns, unprocessed experiences, and constant “busy-ness” shape the way we show up as leaders, and how we can reconnect with a deeper source of energy, purpose, and wholeness. Suzanne also shares insights from her upcoming book and documentary, It's Deeper Than That: Pathway to a Vibrant, Purposeful Life, and her new leadership program, The Great Reconnection.In this episode, we discuss:• What the self-renewing energy source within each of us really is – and how to access it• Why leaders feel “something is missing” even when life looks successful from the outside• How unresolved trauma and childhood experiences show up in leadership and decision-making• The role of somatic work and energy systems in healing and sustainable leadership• Signs that a team or organization is disconnected – and how to begin repairing trust and culture• Why reconnection is the key leadership skill for the future of work

spotify apple signs roberts vibrant purposeful life

Playmaker's Corner Episode 475: 2026 William Woods, Roberts Wesleyan, and Wingate Women's College Flag Football Previews

Playmaker's Corner

Play Episode Listen Later Dec 15, 2025 69:17

Recorded on 12/12/25. On this episode Coach V previews 3 programs in NAIA William Woods, and D2 programs Roberts Wesleyan and Wingate. For William Woods he talks about last season, and the key storylines there. For all the teams he talks about key athletes, coaches, and does his best predicting some of the games for this upcoming 2026 Women's College flag football season. Intro 0:00- 2:34William Woods Preview 2:35- 29:40Roberts Wesleyan Preview 29:41- 41:48Wingate Preview 41:49- 1:05:53Outro 1:05:54- 1:09:18instagram.com/playmakerscorner/?hl=en⁠Facebook: ⁠https://www.facebook.com/PlaymakerCorner⁠Youtube: ⁠https://www.youtube.com/channel/UCUEcv0BIfXT78kNEtk1pbxQ/featured⁠ Twitch: ⁠https://www.twitch.tv/playmakerscorner⁠ Website: ⁠https://playmakerscorner.com/⁠ Listen to us on:Spotify: ⁠https://open.spotify.com/show/4rkM8hKtf8eqDPy2xqOPqr⁠ Apple Podcasts: ⁠https://podcasts.apple.com/us/podcast/the-cycle-365/id1484493484?uo=4⁠

women spotify college roberts d2 flag football playmakers wesleyan wingate coach v

Prince Andrew And Ghislaine Maxwell Hatch A Plan To Thwart Virginia Roberts Allegations

The Epstein Chronicles

Play Episode Listen Later Dec 14, 2025 24:16 Transcription Available

According to reporting and court filings, Prince Andrew and Ghislaine Maxwell allegedly discussed a plan to discredit the now-infamous photograph showing Andrew with Virginia Roberts by manufacturing “evidence” that the image was fake. Maxwell's family had already circulated a staged photo meant to mimic the layout of her London townhouse bathroom in an attempt to claim that the original image couldn't have been taken there. Behind the scenes, Maxwell and Andrew allegedly explored additional ways to undermine the photo's authenticity, including commissioning experts to pick apart shadows, angles, and metadata in hopes of creating enough public doubt to neutralize its impact. The effort wasn't grounded in a definitive forensic flaw—it was an attempt to create a narrative that the photo was unreliable.The alleged plan went further than simply hiring experts. Reports indicated that Maxwell and Andrew hoped to construct an alternative explanation for the image's existence entirely—suggesting it could have been manipulated, misdated, or even fabricated by unknown actors. The strategy relied on fueling skepticism rather than proving a concrete hoax, banking on the idea that if the public believed the picture was questionable, Andrew could distance himself from Roberts' claims. Ultimately, these efforts fizzled because no credible forensic analysis ever supported the idea that the photograph was doctored. Instead, the campaign only drew more scrutiny to Andrew and Maxwell, reinforcing the perception that they were scrambling for any possible way to discredit evidence rather than confronting the substantive allegations.to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

donald trump news reports roberts breaking news jeffrey epstein allegations ghislaine maxwell hatch prince andrew

Episode 145 – Chelsea 2-0 Everton | Response, Relief & Bluesday Preview

Chelsea Against The World

Play Episode Listen Later Dec 13, 2025 46:20

Chelsea finally return to winning ways with a 2-0 victory over Everton, and Chelsea Against The World is back to break it all down. After a rough run of form and a mountain of criticism, Manny and Simon praise the reaction from both the players and Enzo Maresca, who needed this response badly.The hosts highlight the impact of Malo Gusto, Cole Palmer, Wesley Fofana, and Robert Sánchez, whose performances helped steady the ship and restore some confidence around the club.Attention then turns to the Carabao Cup clash against Cardiff City (League One). With rotation expected, Manny and Simon are clear; a win is non-negotiable.PLUS a special segment with Roy, Ben, and Dylan from Carefree Louisiana, previewing our next live podcast with Chelsea legend Paul Canoville at Bluesday in New Orleans (February 6–8). We talk community, culture, and why this is shaping up to be a special weekend for Chelsea fans in the US.

attention relief roberts manny everton carabao cup enzo maresca wesley fofana malo gusto paul canoville

Viriginia Roberts And Her Battle In The Courtroom To Expose Jane Doe # 133

The Epstein Chronicles

Play Episode Listen Later Dec 13, 2025 9:56 Transcription Available

Virginia Roberts is battling it out in court with someone known as Jane doe # 133. The battle has to do with Jane Doe's persistent resistance to her name being unsealed as part of the document dump initiated by Judge Preska. Virginia Roberts and her legal team say that transparency and the publics right to know outweighs Jane doe's right to privacy, considering she has already been named in public. Now it will be up to the court to decide.to contact me:bobbycapucci@protonmail.comsource:Jeffrey Epstein Victim Virginia Giuffre Fighting Jane Doe's Objection to Unsealing of Records (radaronline.com)Become a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

donald trump battle news records roberts breaking news jeffrey epstein expose courtroom ghislaine maxwell prince andrew jane doe objection viriginia

Ep. 213 - The 257 Roberts – A Classic That Still Delivers

The Hornady Podcast

Play Episode Listen Later Dec 12, 2025 41:30

Host Seth Swerczek is joined by Preston Lentfer and Matt Ritchie to explore the history and lasting value of the 257 Roberts cartridge. They discuss its origins, ballistics, versatility, and why this classic still holds its own in the modern era of hunting and shooting.

roberts delivers matt ritchie

Hour 1

Declare Your Independence with Ernest Hancock - Radio

Play Episode Listen Later Dec 12, 2025 52:14

freedom player active stream roberts

12/5/25 Mark Thornton on the Boom Bust Cycle and the Federal Reserve

The Libertarian Institute - All Podcasts

Play Episode Listen Later Dec 11, 2025 56:13

Mark Thornton of the Mises Institute joins the show to talk about the state of the economy, the boom bust cycle and why anybody—left, right, and center—who cares about the wellbeing of the working class needs to oppose the existence of the Federal Reserve. Discussed on the show: “The Seven Deadly Economic Sins” (Mises.org) The Minor Issues Podcast Mark Thornton is a senior fellow at the Mises Institute. His most recent book is The Skyscraper Curse: And How Austrian Economists Predicted Every Major Economic Crisis of the Last Century. Follow him on Twitter @DrMarkThornton Audio cleaned up with the Podsworth app: https://podsworth.com Use code HORTON50 for 50% off your first order at Podsworth.com to clean up your voice recordings, sound like a pro, and also support the Scott Horton Show! For more on Scott's work: Check out The Libertarian Institute: https://www.libertarianinstitute.org Check out Scott's other show, Provoked, with Darryl Cooper https://youtube.com/@Provoked_Show Read Scott's books: Provoked: How Washington Started the New Cold War with Russia and the Catastrophe in Ukraine https://amzn.to/47jMtg7 (The audiobook of Provoked is being published in sections at https://scotthortonshow.com) Enough Already: Time to End the War on Terrorism: https://amzn.to/3tgMCdw Fool's Errand: Time to End the War in Afghanistan https://amzn.to/3HRufs0 Follow Scott on X @scotthortonshow And check out Scott's full interview archives: https://scotthorton.org/all-interviews This episode of the Scott Horton Show is sponsored by: Roberts and Roberts Brokerage Incorporated https://rrbi.co Moon Does Artisan Coffee https://scotthorton.org/coffee; Tom Woods' Liberty Classroom https://www.libertyclassroom.com/dap/a/?a=1616 and Dissident Media https://dissidentmedia.com You can also support Scott's work by making a one-time or recurring donation at https://scotthorton.org/donate/https://scotthortonshow.com or https://patreon.com/scotthortonshow Learn more about your ad choices. Visit megaphone.fm/adchoices

12/5/25 Mark Thornton on the Boom-Bust Cycle and the Federal Reserve

Play Episode Listen Later Dec 11, 2025 55:58

Download Audio. Mark Thornton of the Mises Institute joins the show to talk about the state of the economy, the boom bust cycle and why anybody—left, right, and center—who cares about the wellbeing of the working class needs to oppose the existence of the Federal Reserve. Discussed on the show: “The Seven Deadly Economic Sins” (Mises.org) The Minor Issues Podcast Mark Thornton is a senior fellow at the Mises Institute. His most recent book is The Skyscraper Curse: And How Austrian Economists Predicted Every Major Economic Crisis of the Last Century. Follow him on Twitter @DrMarkThornton Audio cleaned up with the Podsworth app: https://podsworth.com Use code HORTON50 for 50% off your first order at Podsworth.com to clean up your voice recordings, sound like a pro, and also support the Scott Horton Show! For more on Scott's work: Check out The Libertarian Institute: https://www.libertarianinstitute.org Check out Scott's other show, Provoked, with Darryl Cooper https://youtube.com/@Provoked_Show Read Scott's books: Provoked: How Washington Started the New Cold War with Russia and the Catastrophe in Ukraine https://amzn.to/47jMtg7 (The audiobook of Provoked is being published in sections at https://scotthortonshow.com) Enough Already: Time to End the War on Terrorism: https://amzn.to/3tgMCdw Fool's Errand: Time to End the War in Afghanistan https://amzn.to/3HRufs0 Follow Scott on X @scotthortonshow And check out Scott's full interview archives: https://scotthorton.org/all-interviews This episode of the Scott Horton Show is sponsored by: Roberts and Roberts Brokerage Incorporated https://rrbi.co Moon Does Artisan Coffee https://scotthorton.org/coffee; Tom Woods' Liberty Classroom https://www.libertyclassroom.com/dap/a/?a=1616 and Dissident Media https://dissidentmedia.com You can also support Scott's work by making a one-time or recurring donation at https://scotthorton.org/donate/https://scotthortonshow.com or https://patreon.com/scotthortonshow

12/5/25 Brandt Burleson on How He Helped Israel Propagandize American Christians

Play Episode Listen Later Dec 10, 2025 45:22

Scott interviews Brandt Burleson about how he stumbled into his former job at an Israeli consulate, what they had him doing, why they were interested in him and what he thinks of all that now. Discussed on the show: Creative Chaos: Inside the CIA's Covert War to Topple the Syrian Government by William Van Wagenen “The Alawite women taken as sex slaves in Syria” (The Spectator) “Inside Syria's state-backed cover-up of Alawite women's kidnappings” (The Cradle) Brandt Burleson holds a MA in International Affairs from American University. He worked as the Strategic Outreach Director for the Consulate General of Israel to the Southwest United States for over eight years. Before that, he planned business and policy programs for Asia Society Texas Center. He now publishes regularly at The Libertarian Institute. Audio cleaned up with the Podsworth app: https://podsworth.com Use code HORTON50 for 50% off your first order at Podsworth.com to clean up your voice recordings, sound like a pro, and also support the Scott Horton Show! For more on Scott's work: Check out The Libertarian Institute: https://www.libertarianinstitute.org Check out Scott's other show, Provoked, with Darryl Cooper https://youtube.com/@Provoked_Show Read Scott's books: Provoked: How Washington Started the New Cold War with Russia and the Catastrophe in Ukraine https://amzn.to/47jMtg7 (The audiobook of Provoked is being published in sections at https://scotthortonshow.com) Enough Already: Time to End the War on Terrorism: https://amzn.to/3tgMCdw Fool's Errand: Time to End the War in Afghanistan https://amzn.to/3HRufs0 Follow Scott on X @scotthortonshow And check out Scott's full interview archives: https://scotthorton.org/all-interviews This episode of the Scott Horton Show is sponsored by: Roberts and Roberts Brokerage Incorporated https://rrbi.co Moon Does Artisan Coffee https://scotthorton.org/coffee; Tom Woods' Liberty Classroom https://www.libertyclassroom.com/dap/a/?a=1616 and Dissident Media https://dissidentmedia.com You can also support Scott's work by making a one-time or recurring donation at https://scotthorton.org/donate/https://scotthortonshow.com or https://patreon.com/scotthortonshow Learn more about your ad choices. Visit megaphone.fm/adchoices

12/5/25 William Van Wagenen on Life in Post-Assad Syria

Play Episode Listen Later Dec 10, 2025 45:35

Scott interviews William Van Wagenen about some of the horrific crimes taking place in Syria now that Bin Ladenite Islamists have taken over the country. They explore some of these stories and discuss the level of attention these are getting in the Western press and the broader geopolitical context behind this consequential regime change. Discussed on the show: Creative Chaos: Inside the CIA's Covert War to Topple the Syrian Government by William Van Wagenen “The Alawite women taken as sex slaves in Syria” (The Spectator) “Inside Syria's state-backed cover-up of Alawite women's kidnappings” (The Cradle) William Van Wagenen is the author of Creative Chaos: Inside the CIA's Covert War to Topple the Syrian Government. He has a BA in German literature From Brigham Young University and an MA in Theological Studies from Harvard Divinity School. You can read his other writings on Syria for the Libertarian Institute here. Follow him on Twitter @wvanwagenen Audio cleaned up with the Podsworth app: https://podsworth.com Use code HORTON50 for 50% off your first order at Podsworth.com to clean up your voice recordings, sound like a pro, and also support the Scott Horton Show! For more on Scott's work: Check out The Libertarian Institute: https://www.libertarianinstitute.org Check out Scott's other show, Provoked, with Darryl Cooper https://youtube.com/@Provoked_Show Read Scott's books: Provoked: How Washington Started the New Cold War with Russia and the Catastrophe in Ukraine https://amzn.to/47jMtg7 (The audiobook of Provoked is being published in sections at https://scotthortonshow.com) Enough Already: Time to End the War on Terrorism: https://amzn.to/3tgMCdw Fool's Errand: Time to End the War in Afghanistan https://amzn.to/3HRufs0 Follow Scott on X @scotthortonshow And check out Scott's full interview archives: https://scotthorton.org/all-interviews This episode of the Scott Horton Show is sponsored by: Roberts and Roberts Brokerage Incorporated https://rrbi.co Moon Does Artisan Coffee https://scotthorton.org/coffee; Tom Woods' Liberty Classroom https://www.libertyclassroom.com/dap/a/?a=1616 and Dissident Media https://dissidentmedia.com You can also support Scott's work by making a one-time or recurring donation at https://scotthorton.org/donate/ https://scotthortonshow.com or https://patreon.com/scotthortonshow Learn more about your ad choices. Visit megaphone.fm/adchoices

S8 Ep168: Views on America and Marxist Dogma: Colleague Geoffrey Roberts explains that Stalin admired American production and the Constitution, viewing the U.S. as a progressive capitalist state; however, Stalin remained a Marxist dogmatist who edited tex

america american production views constitution progressive roberts edited joseph stalin dogma marxist geoffrey colleagues capitalist admired bolshevism

Play Episode Listen Later Dec 7, 2025 7:31

Views on America and Marxist Dogma: Colleague Geoffrey Roberts explains that Stalin admired American production and the Constitution, viewing the U.S. as a progressive capitalist state; however, Stalin remained a Marxist dogmatist who edited texts to fit his ideology, with Roberts ultimately characterizing Stalin as an intellectual whose worldview was limited by his fanatical commitment to Bolshevism. 1934

S8 Ep168: Rehabilitating Ivan the Terrible: Colleague Geoffrey Roberts reports that Stalin favored the narrative history of Robert Vipper, who rehabilitated Ivan the Terrible as a state-builder rather than a cruel tyrant; Stalin criticized Eisenstein's f

history narrative terrible reports roberts builder joseph stalin cruel geoffrey colleagues tyrant favored criticized eisenstein rehabilitating ivan the terrible rehabilitated

Play Episode Listen Later Dec 6, 2025 12:59

Rehabilitating Ivan the Terrible: Colleague Geoffrey Roberts reports that Stalin favored the narrative history of Robert Vipper, who rehabilitated Ivan the Terrible as a state-builder rather than a cruel tyrant; Stalin criticized Eisenstein's film sequel for portraying Ivan as weak, insisting Ivan's terror was a necessary defense of the state, a view justifying Stalin's own purges. 1945

S8 Ep168: Stalin's Early Education and Reading Habits: Colleague Geoffrey Roberts describes Stalin's Blizhnyaya dacha, where the dictator kept a massive library and died in 1953, detailing Stalin's youth as a pious, star seminary student who lost inter

lost youth student massive library died roberts inter joseph stalin geoffrey colleagues seminary describes dictator detailing pious early education reading habits dacha

Play Episode Listen Later Dec 6, 2025 11:32

Stalin's Early Education and Reading Habits: Colleague Geoffrey Roberts describes Stalin's Blizhnyaya dacha, where the dictator kept a massive library and died in 1953, detailing Stalin's youth as a pious, star seminary student who lost interest in the priesthood after discovering a radical bookshop, becoming a voracious reader of prohibited nationalist and socialist literature. 1939

S8 Ep168: Stalin's Early Education and Reading Habits: Colleague Geoffrey Roberts describes Stalin's Blizhnyaya dacha, where the dictator kept a massive library and died in 1953, detailing Stalin's youth as a pious, star seminary student who lost inter

lost youth student massive library died roberts inter joseph stalin geoffrey colleagues seminary describes dictator detailing pious early education reading habits dacha

Play Episode Listen Later Dec 6, 2025 7:55

Stalin's Early Education and Reading Habits: Colleague Geoffrey Roberts describes Stalin's Blizhnyaya dacha, where the dictator kept a massive library and died in 1953, detailing Stalin's youth as a pious, star seminary student who lost interest in the priesthood after discovering a radical bookshop, becoming a voracious reader of prohibited nationalist and socialist literature. 1921

S8 Ep168: Classifying the Dictator's Collection: Colleague Geoffrey Roberts reports that Stalin hired Lenin's former librarian to organize his growing collection, creating a handwritten classification scheme that prioritized Marxist thinkers, surprising

Play Episode Listen Later Dec 6, 2025 13:52

Classifying the Dictator's Collection: Colleague Geoffrey Roberts reports that Stalin hired Lenin's former librarian to organize his growing collection, creating a handwritten classification scheme that prioritized Marxist thinkers, surprisingly ranking his rival Trotsky highly on this reading list; the Bolsheviks seized control of publishing to manage public thought, while Stalin adopted an ex libris stamp to identify his personal books. 1930

S8 Ep168: Personal Tragedy and the Dacha Library: Colleague Geoffrey Roberts recounts that following the suicide of his wife Nadia in 1932, Stalin became more isolated, moving his routine to the Blizhnyaya dacha, which became the "center of gravity&q

moving personal wife suicide tragedy routine library roberts joseph stalin geoffrey colleagues isolated machiavelli recounts center of gravity dacha

Play Episode Listen Later Dec 6, 2025 6:43

Personal Tragedy and the Dacha Library: Colleague Geoffrey Roberts recounts that following the suicide of his wife Nadia in 1932, Stalin became more isolated, moving his routine to the Blizhnyaya dacha, which became the "center of gravity" for his books eventually numbering around 25,000, suggesting that like Machiavelli, Stalin felt most among friends when surrounded by his library. 1934

S8 Ep168: Rediscovering the Scattered Library: Colleague Geoffrey Roberts explains that after 1956, Stalin's library was dispersed, leaving only about 5,500 identifiable books, some containing his pometki or markings; while Yuri Sharapov revealed the lib

books leaving revealed library roberts joseph stalin rediscovering geoffrey colleagues yuri scattered markings dispersed identifiable sharapov

Play Episode Listen Later Dec 6, 2025 8:04

Rediscovering the Scattered Library: Colleague Geoffrey Roberts explains that after 1956, Stalin's library was dispersed, leaving only about 5,500 identifiable books, some containing his pometki or markings; while Yuri Sharapov revealed the library in 1988, no "smoking gun" explains Stalin, with Roberts arguing the library proves Stalin was a serious intellectual who believed books changed the world. 1902

S8 Ep168: Historical Influences: Bismarck and Realpolitik: Colleague Geoffrey Roberts discusses how Stalin studied Bismarck as a fellow modernizer who executed a "revolution from above" to build a strong state, arguing that regarding Machiavelli